Business Context and Reporting Period
Company: Aclaris Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 18, 2015
Reporting Period: Third Quarter ended September 30, 2015
This filing serves as a notification that the company issued a press release on November 18, 2015, announcing its financial results for the quarter ended September 30, 2015. The detailed results are contained in Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover document for the Form 8-K and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms the issuance of the third-quarter 2015 financial results.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. It explicitly states that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 18, 2015) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the third-quarter 2015 operational results and any updates to clinical trial progress.
- Check for any forward-looking statements or guidance provided in the full press release text.
- Confirm the company's cash runway and funding status as detailed in the full financial report.